-
14 Comments
Bristol-Myers Squibb Company is currently in a long term uptrend where the price is trading 5.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.
Bristol-Myers Squibb Company's total revenue rose by 39.3% to $11B since the same quarter in the previous year.
Its net income has dropped by 849.5% to $-10B since the same quarter in the previous year.
Finally, its free cash flow grew by 89.5% to $3B since the same quarter in the previous year.
Based on the above factors, Bristol-Myers Squibb Company gets an overall score of 4/5.
![]() |
Equity Stats
Follow
4 years, 3 months ago
|
![]() |
TradeWithAlerts
Follow
4 years, 3 months ago
|
![]() |
Mike Mercker
Follow
4 years, 3 months ago
|
![]() |
James Lawrence
Follow
4 years, 3 months ago
|
Exchange | NYSE |
---|---|
CurrencyCode | USD |
ISIN | US1101221083 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Market Cap | 97B |
---|---|
Beta | 0.41 |
PE Ratio | 17.87 |
Target Price | 57.8386 |
Dividend Yield | 5.1% |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BMY using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025